American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

American Head & Neck Society | AHNS


The mission of the AHNS is to advance Education, Research, and Quality of Care for the head and neck oncology patient.

  • About
    • Mission Statement and Purpose
    • Divisions & Services of the Society
      • Education
        • Scientific Program/Resident Courses
        • Surgical Videos
        • Journal Club
        • Journals
        • Global Outreach
        • Awards
          • Margaret F. Butler Award
      • Diversity, Equity and Inclusion Division
      • Patient Care
        • Cancer Survivorship
          • Patient Education on Post-Treatment Care
          • Interviews with Cancer Survivors
        • Cancer Prevention
          • SLIDE DECK: HPV-Related Oropharyngeal Cancer
        • Guidelines/Position Statements
        • Find-A-Physician
      • Research
        • Grant Information
        • Clinical Trial
        • Tissue Banks
      • Administrative Divison
        • Development Service Process for Evaluating Projects Requiring Funding
    • Leadership
    • History
      • Society Background
      • AHNS History Interviews
      • Past Presidents
      • In Memory
    • AHNS Newsletter
    • Professionalism & Ethics
    • AHNS Policies and Procedures (P&P) Manual
    • AHNS Foundation
    • AHNS Bylaws
    • AHNS Staff
    • AHNS News and Announcements
    • COVID-19 Bulletin Board
  • Heads Up!
  • Post a Job
  • Meetings
    • AHNS Virtual Education Series
      • TORS Webinar Series
    • AHNS Meetings Info
    • AHNS Call For Abstracts
    • AHNS Call For Late Breaking Abstracts
    • Exhibitor and Support Opportunities
    • Past Meetings
    • Related Meetings
  • For Patients
  • For Trainees
    • Accredited Fellowships
      • Fellowship Match
      • Directory of Fellowships
      • Fellowship Curriculum
      • Certificate of Completion Request
      • Fellowship Graduates
      • For Program Directors
      • For Current AHNS Fellows
    • AHNS Surgical Videos
    • Fellows’ Virtual Tumor Boards
    • Cutaneous Cancer
  • Sections
    • Endocrine Surgery
    • Skull Base Surgery Section
    • Reconstructive Head & Neck Surgery
    • Mucosal Malignancy Section
      • Mucosal Malignancy Section Patient Information
    • Salivary Gland
    • Cutaneous Cancer
  • Member Central
    • Join AHNS
    • Find-A-Physician
    • Mailing List Order
  • Log In
  • Donate

Published on June 4, 2020 by Natalie Silver

AHNS Basic Science/Translational Newsletter Vol 3

Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomized trial

Anthony C Nichols, Julie Theurer, Eitan Prisman, Nancy Read, Eric Berthelet….David A Palma

From Clinical Trial. The Lancet. Oncology, October 2019; 20(10):1349-1359.

Article Review by Natalie Silver, MD

Background/Hypothesis:

Design: Investigator-initiated, multicenter, international, open label, parallel-group, phase 2, randomized clinical trial comparing T1-T2, N0-2 OPSCC patients randomized to either primary radiotherapy (70Gy, chemotherapy if N1-N2) or TORS plus neck dissection (with/without pathologic based adjuvant chemo/radiotherapy). The primary endpoint was swallowing-related QOL at 1 year as established by the MD Anderson Dysphagia Inventory (MDADI) score, powered to detect a 10 point improvement (a clinically meaningful change).

Summary of results: 68 patients (34 per group) were randomized over a 5 year period (following stratification by p16 status). MDADI total scores at 1 year were: mean 86.9 (SD 11.4) in the radiotherapy (RT) group and 80.1 (SD 13.0) in the TORS plus neck dissection group (p=0.042), which did not meet the prescribed threshold (10 points) for a clinically meaningful difference. Toxicity patterns differed between the two groups with neutropenia, hearing loss and tinnitus being more common in the in the RT group and more cases of trismus in the TORS plus neck dissection group. The most common adverse events in the RT group were dysphagia (n=6), hearing loss (n-6), and mucositis (n=4) and in the TORS plus neck dissection group, dysphagia was the most common adverse event (n=9) and there was one patient death caused by bleeding after TORS. Oncologic outcomes were similar in both groups.

Strengths:

  • Well-designed, prospective randomized clinical trial..
  • Highest level of evidence for a clinical study (Level I evidence).
  • Multi-institutional and international trial.which was not measured in this study.
  • MDADI is a commonly used and validated swallowing QOL assessment tool.

 Weaknesses

  • Modest sample size and was not powered to compare survival outcomes.
  • Institutional differences in criteria for administration of adjuvant therapy may be confounding.
  • Radiotherapy has late side effects, specifically with respect to dysphagia and the swallowing QOL scores may worsen more considerably in the radiotherapy group >1 year after treatment,  which was not measured in this study.

Key Points:

  • While this study did not show clinically meaningful differences in swallowing QOL scores at 1 year, this is the only prospective randomized controlled clinical trial published, to date, to address this concern.
  • Tese findings conflict with previous non-randomized comparisons of radiotherapy with TORS which have found that both modalities achieved similar oncologic outcomes, but that functional outcomes appeared better with TORS (Yeh et al, systematic review 2015).
  • Much of the QOL data (not only swallowing data) in this study favored radiotherapy. The surgical group had a clinically meaningful decline in scores for “Global” (p=0.024) and “Emotional” (p=0.021) subscales. These differences (when compared to retrospective studies) may be due to bias in the retrospective reviews that included advanced T –stage patients not amenable to TORS, or early studies prior to IMRT.
  • In a multidisciplinary setting, it is important for clinicians to understand and counsel our patients in both surgical and non-surgical treatment options, since there are differences in risks and toxicity patterns for the two treatment modalities. Studies, like ORATOR, may be used as a guide, but additional clinical research is needed and discussions about treatment options should be personalized to each individual patient and institution.
  • The results from several more clinical trials will provide high quality evidence for outstanding questions that can help guide us to tailor treatment for OPSCC patients, these include; the QoLATI trial (with similar cohorts and endpoints to ORATOR), ECOG 3311 (NCT01898494) and the ORATOR2 trial (NCT03210103).

From the Basic Science/Translational Service
Jeffrey C. Liu MD Vice Chair
Richard Wong MD Chair

  • Bio
  • Latest Posts
Natalie Silver

Natalie Silver

Natalie Silver MD, MS, FACS is an Assistant Professor in the Department of Otolaryngology, Head and Neck Surgery, Division of Surgical Oncology, at the University of Florida. She is the UFHealth Cancer Center Head and Neck Cancer Disease Site Group Research Leader. Dr. Silver has an active clinical practice treating head and neck cancer patients. She is also PI of a translational research lab focused on developing therapeutic oral cancer vaccines and investigating the role of the microbiome in the development and progression of oral cancer.
Natalie Silver

Latest posts by Natalie Silver (see all)

  • AHNS Basic Science/Translational Newsletter Vol 3 - June 4, 2020

 

 

Views: 0

Share:

  • Facebook
  • Twitter
  • LinkedIn

Related

Subscribe to Heads Up!

Enter your email address to subscribe to Heads Up! and receive notifications of new posts by email.

Join 204 other subscribers

AHNS Meetings

WEBINAR CALENDAR

AHNS Call For Abstracts

News and Announcements

  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – Final Day To Submit Abstracts March 22, 2023
  • ARS NASBS AHNS Sinonasal Cancer Collaborative – Sinonasal Malignancy Virtual Tumor Board March 20, 2023
  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts March 16, 2023
  • Registration for the AHNS 2023 is now open! March 10, 2023
  • What’s New on the AHNS Website March 9, 2023

AHNS on Facebook

AHNS on Facebook

Contact Us

AHNS, 11300 W. Olympic Blvd, Suite 600
Los Angeles, CA 90064
ph: (310) 437-0559 / fx: (310) 437-0585
[email protected]

Search this website

Follow the AHNS

  • Email
  • Facebook
  • Twitter
  • YouTube

Recent Heads Up! Posts

AHNS 2023 Meeting – Late Breaking Call For Abstracts – Final Day To Submit Abstracts

ARS NASBS AHNS Sinonasal Cancer Collaborative – Sinonasal Malignancy Virtual Tumor Board

AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts

More News and Announcements

© 2002–2023 American Head and Neck Society · Privacy and Return Policy
· Managed by BSC Management, Inc